BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 33962579)

  • 1. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.
    Calais J; Zhu S; Hirmas N; Eiber M; Hadaschik B; Stuschke M; Herrmann K; Czernin J; Kishan AU; Nickols NG; Elashoff D; Fendler WP
    BMC Cancer; 2021 May; 21(1):512. PubMed ID: 33962579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized prospective phase III trial of
    Calais J; Czernin J; Fendler WP; Elashoff D; Nickols NG
    BMC Cancer; 2019 Jan; 19(1):18. PubMed ID: 30616601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Impact of
    Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
    J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma.
    Mena E; Shih J; Chung JY; Jones J; Rabiee A; Monge C; Turkbey B; Lindenberg L; Salerno KE; Kassin M; Wood B; Hernandez J; Maass-Moreno R; Saboury B; Jakhete N; Molitoris JK; Unger KR; Choyke PL; Escorcia FE
    PLoS One; 2022; 17(11):e0277407. PubMed ID: 36367894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
    Hofman MS; Lawrentschuk N; Francis RJ; Tang C; Vela I; Thomas P; Rutherford N; Martin JM; Frydenberg M; Shakher R; Wong LM; Taubman K; Ting Lee S; Hsiao E; Roach P; Nottage M; Kirkwood I; Hayne D; Link E; Marusic P; Matera A; Herschtal A; Iravani A; Hicks RJ; Williams S; Murphy DG;
    Lancet; 2020 Apr; 395(10231):1208-1216. PubMed ID: 32209449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT.
    Karagiannis V; Wichmann V; Saarinen J; Eigeliene N; Andersen H; Jekunen A
    Radiat Oncol; 2022 Jan; 17(1):19. PubMed ID: 35093103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
    Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol.
    Staal FHE; Janssen J; Brouwer CL; Langendijk JA; Ng Wei Siang K; Schuit E; de Jong IJ; Verzijlbergen JF; Smeenk RJ; Aluwini S
    BMC Cancer; 2022 Apr; 22(1):416. PubMed ID: 35428210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
    Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
    BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
    Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
    Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using
    Zamboglou C; Sachpazidis I; Koubar K; Drendel V; Wiehle R; Kirste S; Mix M; Schiller F; Mavroidis P; Meyer PT; Werner M; Grosu AL; Baltas D
    Radiother Oncol; 2017 Jun; 123(3):472-477. PubMed ID: 28499607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of
    Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
    Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of prostate cancer with
    Bodar YJL; Jansen BHE; van der Voorn JP; Zwezerijnen GJC; Meijer D; Nieuwenhuijzen JA; Boellaard R; Hendrikse NH; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN
    World J Urol; 2021 Jul; 39(7):2439-2446. PubMed ID: 33079250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multicenter Prospective Clinical Trial of
    McCarthy M; Francis R; Tang C; Watts J; Campbell A
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in prostate-specific membrane antigen PET of prostate cancer.
    Bouchelouche K; Choyke PL
    Curr Opin Oncol; 2018 May; 30(3):189-196. PubMed ID: 29465429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
    Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
    Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSMA-PET/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): Findings of Detection Rate, Effect on Cancer Management, and Early Toxicity From a Phase 2 Randomized Controlled Trial.
    Petit C; Delouya G; Taussky D; Barkati M; Lambert C; Beauchemin MC; Clavel S; Mok G; Paré AG; Nguyen TV; Duplan D; Keu KV; Saad F; Juneau D; Ménard C
    Int J Radiat Oncol Biol Phys; 2023 Jul; 116(4):779-787. PubMed ID: 36639035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study.
    Donswijk ML; van Leeuwen PJ; Vegt E; Cheung Z; Heijmink SWTPJ; van der Poel HG; Stokkel MPM
    BMC Cancer; 2020 Aug; 20(1):723. PubMed ID: 32758168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.